We review the most well characterized long non-coding RNAs (lncRNAs) with important roles in hallmarks of cancer, additionally including lncRNAs with a higher poten- 
ANRIL (antisense noncoding RNA in the INK4 locus) has been reported to recruit PRC2 and PRC1 complexes and repress gene expression. 17 Post-transcriptionally, lncRNAs are involved in every step of RNA metabolism, such as splicing, nuclear export, localization and mRNA decay, as well as protein translation and stability. [18] [19] [20] [21] [22] In the cytoplasm, lncRNAs may work as decoys, by sequestering proteins from their usual targets. A good example is the lncRNA NORAD, which has multiple binding sites for Pumilio (PUM) proteins. The main function of these proteins is to bind to their mRNA targets, driving them to degradation. The recruitment of PUM by NORAD alters the half-life of those mRNAs. 23 LncRNAs can also work as binding platforms (known as competing endogenous RNAs, ceRNAs) for miRNAs and proteins, preventing them from binding to their usual targets. 24 Even though they are described as non-coding RNAs, new studies have reported the functional micropeptides derived from some of them. 25, 26 LncRNAs were neglected for a long time as possible molecular markers or therapeutic targets because they were initially considered as transcriptional noise. Recently, however, these transcripts have attracted the significant attention of researchers as a result of their role in genetic regulation, including epigenetic, transcriptional and posttranscriptional regulation, 27 being involved in numerous biological processes, as well as being associated with multifactorial diseases, 28, 29 although, for most of lncRNAs, their biological roles remain unidentified.
Cancer is the multifactorial disease with the largest number of studies investigating the role of lncRNAs. LncRNA deregulation has been observed in various cancer types and has been associated with various cell processes, such as transcription, intracellular trafficking and chromosome remodeling. 30, 31 The hallmarks of cancer described by Hanahan and Weinberg 32 include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis and activating invasion/metastasis. Additionally, in 2011, genome instability, inflammation, reprogramming of energy metabolism and evading immune destruction were added as important aspects during the multistep development of human tumors. 33 LncRNAs are implicated in almost all hallmarks of cancer ( Figure 1) and, accordingly, we review the most well characterized roles of these molecules in each of them, additionally including lncRNAs with high potential for clinical application.
| LNCRNAS IN HALLMARKS OF CANCER

| Sustaining proliferative signaling
One of the main differences between normal and tumor cells is the acquired ability of cancer cells to sustain proliferative signaling in the absence of external stimuli. Normal cells exhibit a highly controlled production and release of growth signals, which allows homeostasis and, thus, the maintenance of normal tissue architecture and function.
By contrast, tumor cells may have lost this capacity, resulting in unlimited growth, 33 a process in which lncRNAs have been described to play an important role.
An important lncRNA involved in growth signaling pathway is CAR10. It has been observed that CAR10 up-regulates the transcriptional rate of the epidermal growth factor receptor (EGFR) gene by
FIGURE 1
LncRNAs associated with the hallmarks of cancer (image source: Mind the Graph platform; https://mindthegraph.com) directly binding to a specific transcription factor YB-1 in lung cancer cells. 34 The imprinted lncRNA H19 is also an example of a regulator of receptor abundance. H19 acts as a sponge for let-7 miRNA, which is capable of reducing IGFR1. 35 Additionally, the H19 gene is also a precursor of miR-675. H19-derived miR-675 increases stability and activation of EGFR protein by direct down-regulation of ubiquitin protein ligases.
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LINC00152 has been identified as an oncogene related to several cancer types, such as gastric, hepatocellular and colon cancers. 37 Additionally, LINC00152 may directly bind to EGFR protein, causing activation of this receptor and also the phosphoinositide 3-kinase (PI3K)/Akt pathway.
38
FGFR3 antisense transcript 1 (FGFR3-AS1) is up-regulated in osteosarcoma and presents increased expression associated with large tumors and metastasis. FGFR3-AS1 may act in direct association with FGFR3 mRNA, increasing the stability of this transcript.
39
MA-LINC1 (mitosis-associated long intergenic non-coding RNA1)
is associated with cancer cell proliferation by regulating the cell cycle.
Inhibition of MA-LINC1 leads to a decrease of cells in G1 phase and an increase in all other stages, particularly cells in G2/M phase. This regulation mechanism is acquired by cis repression of a neighboring gene, PURα, which is also a cell cycle regulator.
40
HOTAIR (HOX transcript antisense RNA) has been associated with many processes, such as proliferation, apoptosis and invasiveness. The up-regulation of HOTAIR has been observed in many types of cancer, such as breast, colon, hepatocellular and gastric cancers. 41 Knockdown of HOTAIR induced significantly decreased proliferation via regulation of the p53/Akt/JNK signaling pathway. 42 Another mechanism of proliferation regulation via HOTAIR was reported in pancreatic cancer cells. HOTAIR induces histone modifications on the miR-663b
promoter, resulting in repression of this microRNA and, indirectly, up-regulation of IGF2. 43 In retinoblastoma and cervical cancer, the NOTCH signaling pathway was abnormally activated as a consequence of HOTAIR up-regulation. 44, 45 Prostate cancer-associated transcript 1 (PCAT-1) is a lncRNA that was originally identified as deregulated in prostate cancer. However, high expression levels of PCAT-1 have been observed in several types of cancer. 46 Additionally, this transcript regulates proliferation via post-transcriptional stabilization of the c-MYC.
47
Cell growth is strongly influenced by glucocorticoids. In this context, it was observed that lncRNA GAS5 (Growth Arrest Specific 
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H19 is also associated with evasion of growth suppression. The H19-derived miR-675 binds to the 3′-UTR of RB mRNA, resulting in negative regulation of this tumor suppressor protein. 54 Additionally, it has been reported that P53 protein can suppress H19 expression and also that H19-derived miR-675 inhibits P53. 55, 56 The LINCRNA-P21 has a key role in regulating P21 levels, a CDK2
inhibitor. In hepatocellular carcinoma, down-regulation of LINCRNA-P21 was observed and, when its expression was induced, cell proliferation and colony formation were inhibited. 57, 58 In gastric cancer, PTENP1 acts as a competing endogenous decoying miR-106b and miR-93, resulting in PTEN high expression. 59 In addition, down-regulation of PTENP1 promotes malignant behaviors in head and neck squamous cell carcinoma. 60 The lncRNA HEIH is highly expressed in hepatitis B virus-related hepatocellular carcinoma and plays an important role in G0/G1 arrest. was knocked down, indicating that this lncRNA is involved in the TSA-induced apoptosis in hepatocellular carcinoma cells.
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GAS5 inhibits proliferation and promotes apoptosis in multiple cancer cell types. 77 In human breast cancer, it was found that different In non-small cell lung cancer cells, ANRIL acts in apoptosis by inhibition of P21 and KLF2 transcription, independently of P15 repression. 81 In bladder cancer cells, increased PARP expression and cleaved Caspase 3/9 were observed with ANRIL knockdown, whereas Caspase 8 was unmodified. Furthermore, BAX and BCL-2 were up-and downregulated, respectively, accompanied by increased cytoplasmic SMAC and cytochrome c, suggesting the involvement of the intrinsic apoptotic pathway.
82
LINCRNA-P21 is a transcriptional target of P53 and hypoxiainducible factor (HIF)-1α and is associated with P53-dependent apoptosis. In non-melanoma skin cancer, TP53 and LINCRNA-P21 are inducible by UVB radiation and they are key mediators of radiationinduced apoptosis. In TP53-mutated cells, UVB radiation does not induce LINCRNA-P21 and cells may escape apoptosis.
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Urothelial carcinoma-associated 1 (UCA1) is a lncRNA involved in embryonic development and carcinogenesis. Overexpression of this lncRNA inhibits apoptosis in prostate cancer cells 84 and activates the Akt pathway in bladder cancer cells. 85 Additionally, UCA1 enhances chemoresistance by activating a set of anti-apoptotic genes and signaling pathways, such as PARP/BCL-2, CREB1/BCL-2/RAB22A, Akt/mTOR and the Wnt signaling pathway. [86] [87] [88] LncRNAs involved in autophagy have also been described. The lncRNA HULC contributes to autophagy activation and inhibits cell apoptosis, contributing to the malignant phenotype of gastric cancer. 89 LncRNA maternally expressed gene 3 (MEG3) can induce apoptosis by activation of P53, 90 and its reduced expression has been found in various tumor types. 91 In bladder cancer, inhibition of MEG3
activates autophagy, increases cell proliferation and suppresses cell apoptosis. 92 Additionally, MEG3 overexpression is associated with apoptosis in prostate cancer cell lines and renal cell carcinoma, associated with BCL-2 decrease and cytochrome c release from mitochondria. 93, 94 Many other lncRNAs have been associated with cell death processes, such as lncRNA-PRAL (P53 regulation-associated lncRNA) 95 and PANDA (P21 associated ncRNA DNA damage activated), 96 highlighting the importance of lncRNAs in the regulation of cell death.
| Enabling replicative immortality
Human cells are normally able to replicate approximately 50 times in cell culture before going through apoptosis. 97 The limited survival rate observed in human cell culture is determined by the progressive telomere shortening, which causes a loss of genetic stability, limiting the number of cell divisions. However, neoplastic cells evade this regulation by expressing telomerase, an enzyme that elongates telomeres by adding telomere repeats to the 3′ end of chromosomes. 98 Interestingly, a key piece involved in the regulation of replicative immortality by inhibiting telomerase is a well described lncRNA named TERRA (telomeric repeat-containing RNA). TERRA is a lncRNA transcribed from telomeric ends whose function is to negatively regulate the activity of telomerase, acting as a tumor suppressor.
99,100
Several cancer cells express low expression of TERRA, suggesting a connection between the longevity of cancer cells and the activity of telomerase.
101,102
| Inducing angiogenesis
The intense proliferative status of tumor tissues depends on a sufficient proportion of vascular irrigation because the high and active metabolism process of these tissues requires the continuous removal of metabolic waste products, as well as an adequate supply of oxygen. 103 Many lncRNAs are involved in the formation of new blood vessels via several biological processes. and MALAT1 promoting angiogenic sprouting in endothelial cells. 115 
| Activating invasion and metastasis
Invasion and metastasis are two major properties of cancer cells, and these abilities are fundamental with respect to differentiating between benign and malignant tumors. 103 The process of invasion and metastasis is a major cause of cancer recurrence and is largely associated with high mortality rates, 116 and several lncRNAs have been observed in the metastatic mechanism. 117 As described previously, HOTAIR was found to be up-regulated in many tumor types and has been associated with many cell processes, playing an important role in promoting epithelial-mesenchymal transition (EMT). 118 In the EMT process, HOTAIR acts by suppressing the expression of several genes related to cell adhesion, such as ASTN1
(astrotactin 1), PCDHA1 and 10 (protocadherin-α 1 and 10), and CLDN11 (Claudin-11), as well as genes involved in mucin production, such as MUC5AC (mucin 5 AC, oligomeric mucus/gel-forming) and
MUC4
. 119 In addition, another mechanism by which HOTAIR mediates EMT is via the repression of some EMT inhibitors such as WNT inhibitory factor 1 (WIF-1) and PTEN. 120, 121 Furthermore, HOTAIR action is required to regulate the expression of matrix metalloproteinases, which has the ability to fragment the extracellular matrix and facilitate invasion.
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MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1) is another lncRNA associated with several cancers. This lncRNA is highly conserved among mammals and is expressed in many normal human tissues. 123, 124 However, it is overexpressed in cancers and is specifically associated with a high metastasis rate and poor prognosis in patients with non-small cell lung carcinoma. 125 Overexpression of In metastatic cells, the lncRNA H19 acts by up-regulating EMTrelated transcription factor SLUG through TGF-β. 55 H19 also exerts its metastatic function by interacting with let-7 or, as seen in pancreatic cancer, hepatocellular carcinoma and lung carcinoma, the overexpression of H19 may result in total ablation of E-cadherin and upregulation of N-cadherin, an important step for acquiring a migratory status. 132, 133 Many other lncRNAs have already been associated with invasion and metastasis in several tumor types, such as CCAT2, treRNA and NKILA in breast cancer, 134, 135 DREH and LET in hepatocellular carcinoma, 61 FENDRR and GCLNC1 in gastric cancer, 136 and SCHLAP1 in prostate cancer. 137 
| Genomic instability
Genomic instability is an important feature in neoplastic cells and could be related to defects in the DNA repair machinery and active telomerase. Certain DNA variations, activating proto-oncogenes or deactivating tumor suppressor genes, may confer a selective advantage on subclones of tumor cells, enabling their survival and outgrowth. 33 Lee et al. 138 described a novel pathway in which the lncRNA NORAD protects cells from aneuploidy. NORAD acts as a sponge that physically binds to PUM1/2 proteins and suppresses protein binding with mRNA common targets, including those necessary for maintaining genomic stability. Thus, the delicate balance between the opposing functions of NORAD and PUM1/2 is critical for the maintenance of genomic stability. 139 An alternative (but not excluding) mechanism to explain the relationship between NORAD and genomic stability was recently proposed by Munschauer et al. 140 They showed that, after subjecting cells to replication stress or DNA damage, a new nuclear ribonucleoprotein complex, named NARC1 (NORAD-activated ribonucleoprotein complex 1), is assembled by NORAD, recruiting proteins known to act as suppressors of genomic instability, such as topoisomerase I (TOP1), ALYREF and the PRPF19-CDC5L. 140 LncRNAs transcribed from α-satellite centromere region physically bind to the chaperone HJURP/CENP-A complex and facilitate the incorporation of CENP-A into centromeric chromatin. 141 In addition, α-satellite RNAs can also interact with the cohesin protector, SGO1, an essential effector for maintaining chromosome stability. 139 The lncRNA DDSR1 (DNA damage-sensitive RNA1) is induced upon DNA damage and its expression is triggered in an ATM/nuclear factor-kappa N (NF-κB) pathway-dependent manner by several DNA In breast cancer cells, NKILA regulates NF-kB signaling. NKILA is induced by NF-kB and binds to NF-kB/IkB complex, inhibiting NFkB signaling. 135 NKILA also regulates T cell sensitivity to activationinduced cell death, an important mechanism exploited by cancers to escape immunological destruction. Additionally, NKILA high expression in tumor-specific cytotoxic T lymphocytes and type 1 helper T cells is associated with a shorter patient survival. 146 Chronic inflammation may be associated with GACAT3, a lncRNA involved in modulating STAT3 signaling. Proliferation of tumor cells was decreased as a result of knockdown of GACAT3. Furthermore,
GACAT3 expression was up-regulated by interleukin (IL)-6
treatment. 147 The lncRNA GAS5 is also associated with inflammatory and immune processes. (i) by directly targeting glycolysis enzymes or (ii) by indirectly targeting the pathways involved in this process. 149 Considering the PI3K/Akt pathway, the lncRNA UCA1 may be involved in this activation. 85 It has been demonstrated previously that Akt can enhance glucose uptake by affecting some glucose transporters, such as GLUT1, GLUT3 and GLUT4. Akt induces GLUT1 and GLUT3 expression and the translocation of GLUT4 to the plasma membrane. 150 Other lncRNAs have been described to participate in the regulation of the PI3K/Akt pathway. HOTAIR has been related to the methylation of the tumor suppressor gene PTEN, 121 and it is well known that PTEN antagonizes PI3K. 151 Therefore, loss of PTEN function allows the over-activation of Akt.
Another way in which lncRNAs participate in tumor metabolism is via the P53 pathway. P53 can inhibit the expression of the glucose transporters GLUT1 and GLUT4, as well as that of phosphoglycerate mutase, an essential enzyme for the glycolytic pathway.
Because MALAT1 has been suggested as a P53 repressor and MEG3 plays an important role in its activation, these lncRNAs may be associated with the reprogramming of energy metabolism in cancer cells. 152, 153 LncRNAs can also be part of the hypoxia pathway. In a low-level 
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PCA3 is an attractive biomarker based on two main features: absent expression in normal and malignant tissues of non-prostate origin and high expression in prostate cancer compared to benign prostatic alteration. 157, 158 Additionally, PCA3 detection has improved the specificity rate for prostate cancer diagnosis. 159 In clinical trials, a treatment protocol for high-risk triple negative breast cancer predicted by the mRNA-lncRNA integrated signature is being evaluated, aiming to validate the efficacy of this lncRNA signature. 160 LncRNA HOTAIR is also being evaluated as a peripheral blood biomarker in thyroid cancer. 161 Although few examples of lncRNAs are currently used in clinical practice, the list of potential biomarkers is large for almost all cancer types (Table 1) . For example, there are numerous descriptions associating polymorphisms, mainly single nucleotide polymorphisms (SNPs), with potential predictive biomarkers for the risk of cancer, including SNPs in ANRIL, MALAT1, HOXA, HULC and PRNCR1.
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Considering RNA expression, several lncRNAs were associated with stage, prognosis and chemotherapy resistance in many different tumor types. 164 Beyond the detection of lncRNAs deregulated in tumor tissues, these molecules have been analyzed in body fluids (whole blood, plasma, urine, gastric juice and saliva) ( Table 2) , suggesting possible non-invasive and more convenient methods that are easily clinically acceptable. 165 In addition to their use in diagnosis, lncRNAs are being investigated with respect to cancer therapy. There are multiple therapeutic strategies being developed to modulate RNA molecules levels, including silencing via small interfering RNA (siRNA), antisense oligonucleotide (ASO) based strategies and other molecular inhibitors further modulating lncRNA expression by gene editing. 166, 167 Among the experimental strategies that target lncRNAs in cancer cells, siRNAs may decrease lncRNA abundance when a synthetic short double-stranded RNA, complementary to the target RNA sequence, is delivered into cells and loaded onto the RNA-induced silencing complex, resulting in the degradation of the target lncRNA. 168 Although this methodology may be functional in many studies, some lncRNAs are not efficiently reduced by siRNA. Because the siRNA machinery is located predominately in the cytoplasm, siRNA silencing is apparently less efficient for nuclear lncRNAs. 169, 170 Alternatively, ASO strategies use modified ASOs to bind target RNA in a mechanism mainly active in the nucleus. 170 Duplex DNA-RNA promotes RNA cleavage by ribonuclease H and decreases the lncRNA target. 171 Both siRNA and ASO methodologies may eventually have off-target effects, highlighting the importance of a proper design and evaluation of specificity.
Given the possibility of unpredictable off-targets, both siRNA and ASO strategies have the inconvenience of incomplete knockdown and transient modulation, mainly when a non-viral delivery system is chosen, such as via lipid particles. A stable lncRNA modulation option is genome editing by clustered regulatory interspaced short palindromic repeats-associated endonuclease 9 (CRISPR/CAS9). The CRISPR/CAS9 system involves the Cas9 nuclease enzyme and a guide RNA that directs Cas9 to its target DNA site and it has been used to generate total or partial deletion of lncRNA. 172 This system may also be used to block lncRNA, by polyadenylation, or to increase lncRNA expression, by inserting a strong promoter upstream of the gene. 172, 173 One of the limitations with respect to applying the CRISPR/Cas9 system to lncRNA modulation is that most of protocols are able to cause small point mutation, although, specifically for non-coding regions, a tiny indel mutation may not necessarily generate functional loss. 173 Additionally, off-target effects may still exist and could result in undesired genetic alterations. Accordingly, although promising, the risks of CRISPR/CAS9 methodology in clinical use still need to be Based on this information, we consider that, although therapeutic technologies for lncRNA modulation has been extensively used in both in vitro and in vivo models, clinical application is promising but still limited. 
